NASDAQ:MGNX - MacroGenics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MacroGenics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.48 -0.04 (-0.38 %) (As of 01/27/2020 11:33 AM ET) Add Compare Today's Range$10.47Now: $10.48▼$10.7150-Day Range$9.27MA: $10.83▼$12.1152-Week Range$7.43Now: $10.48▼$32.32Volume5,616 shsAverage Volume459,129 shsMarket Capitalization$513.10 millionP/E RatioN/ADividend YieldN/ABeta2.31 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGNX Previous Symbol CUSIPN/A CIK1125345 Webhttp://www.macrogenics.com/ Phone301-251-5172Debt Debt-to-Equity Ratio0.11 Current Ratio4.79 Quick Ratio4.79Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$60.12 million Price / Sales8.53 Cash FlowN/A Price / Cash FlowN/A Book Value$5.75 per share Price / Book1.82Profitability EPS (Most Recent Fiscal Year)($4.19) Net Income$-171,450,000.00 Net Margins-303.08% Return on Equity-59.67% Return on Assets-44.82%Miscellaneous Employees364 Outstanding Shares48,960,000Market Cap$513.10 million Next Earnings Date2/25/2020 (Estimated) OptionableOptionable Receive MGNX News and Ratings via Email Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:MGNX Rates by TradingView MacroGenics (NASDAQ:MGNX) Frequently Asked Questions What is MacroGenics' stock symbol? MacroGenics trades on the NASDAQ under the ticker symbol "MGNX." How were MacroGenics' earnings last quarter? MacroGenics Inc (NASDAQ:MGNX) posted its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.94) by $0.03. The biopharmaceutical company had revenue of $18.74 million for the quarter, compared to analyst estimates of $23.33 million. MacroGenics had a negative return on equity of 59.67% and a negative net margin of 303.08%. View MacroGenics' Earnings History. When is MacroGenics' next earnings date? MacroGenics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for MacroGenics. What price target have analysts set for MGNX? 13 brokerages have issued 1-year price objectives for MacroGenics' shares. Their forecasts range from $6.00 to $50.00. On average, they expect MacroGenics' stock price to reach $23.90 in the next twelve months. This suggests a possible upside of 127.2% from the stock's current price. View Analyst Price Targets for MacroGenics. What is the consensus analysts' recommendation for MacroGenics? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MacroGenics. What are Wall Street analysts saying about MacroGenics stock? Here are some recent quotes from research analysts about MacroGenics stock: 1. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (1/23/2020) 2. HC Wainwright analysts commented, "Our 12-month, $39 price target for shares of MacroGenics is based on a 12-year DCF-driven sum-of-the-parts analysis. Our DCF is driven by: beta of 1.8, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 11.5%, and tax rate of 15% beginning in FY 2027. (18%), flotetuzumab (16%) together represent our full target. Risks potentially incurred investing in this stock include: clinical and development, financial, regulatory and reimbursement, and commercial." (5/2/2019) Has MacroGenics been receiving favorable news coverage? News headlines about MGNX stock have been trending somewhat negative on Monday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MacroGenics earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for MacroGenics. Are investors shorting MacroGenics? MacroGenics saw a increase in short interest in December. As of December 31st, there was short interest totalling 3,650,000 shares, an increase of 7.0% from the December 15th total of 3,410,000 shares. Based on an average daily trading volume, of 557,900 shares, the days-to-cover ratio is currently 6.5 days. Currently, 8.3% of the shares of the company are short sold. View MacroGenics' Current Options Chain. Who are some of MacroGenics' key competitors? Some companies that are related to MacroGenics include Prestige Consumer Healthcare (PBH), Aimmune Therapeutics (AIMT), Turning Point Therapeutics (TPTX), Epizyme (EPZM), Heron Therapeutics (HRTX), Eidos Therapeutics (EIDX), Cambrex (CBM), Xencor (XNCR), Ironwood Pharmaceuticals (IRWD), Principia Biopharma (PRNB), Zymeworks (ZYME), Pacira Biosciences (PCRX), Insmed (INSM), Akcea Therapeutics (AKCA) and Arvinas (ARVN). What other stocks do shareholders of MacroGenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Gilead Sciences (GILD), NVIDIA (NVDA), Incyte (INCY), Karyopharm Therapeutics (KPTI), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX) and Micron Technology (MU). Who are MacroGenics' key executives? MacroGenics' management team includes the folowing people: Dr. Scott Koenig, CEO, Pres & Director (Age 67)Mr. James Karrels, Sr. VP, CFO & Sec. (Age 52)Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 65)Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 46)Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 57) Who are MacroGenics' major shareholders? MacroGenics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (2.17%) and Alpine Global Management LLC (0.03%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jeffrey Stuart Peters, Lynn Cilinski, Matthew K Fust and Thomas Spitznagel. View Institutional Ownership Trends for MacroGenics. Which institutional investors are buying MacroGenics stock? MGNX stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Alpine Global Management LLC. View Insider Buying and Selling for MacroGenics. How do I buy shares of MacroGenics? Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is MacroGenics' stock price today? One share of MGNX stock can currently be purchased for approximately $10.52. How big of a company is MacroGenics? MacroGenics has a market capitalization of $515.06 million and generates $60.12 million in revenue each year. The biopharmaceutical company earns $-171,450,000.00 in net income (profit) each year or ($4.19) on an earnings per share basis. MacroGenics employs 364 workers across the globe.View Additional Information About MacroGenics. What is MacroGenics' official website? The official website for MacroGenics is http://www.macrogenics.com/. How can I contact MacroGenics? MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172. MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 328 (Vote Outperform)Underperform Votes: 341 (Vote Underperform)Total Votes: 669MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: What is the float in trading stocks?
